



ELENCO DEGLI AMMESSI AL FINAL CONTEST DEL 26 E 27 NOVEMBRE 2020

SESSIONE STUDI CLINICI

Beatrice ALESSANDRIA | Torino

FOCUS ON PATIENTS WITH TP53 DISRUPTION IN THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 TRIAL: UNIFORM POOR OUTCOME, REGARDLESS OF BASELINE PREDICTORS, MRD STATUS AND LENALIDOMIDE MAINTENANCE

Gregorio BARILÀ | Padova

TREATMENT INDUCED CYTOTOXIC T-CELL MODULATION IN MULTIPLE MYELOMA PATIENTS

Luca BERTAMINI | Torino

HIGH LEVELS OF CIRCULATING PLASMA CELLS IS AN INDEPENDENT HIGH-RISK FEATURES BUT IS MODULATED BY THE ACHIEVEMENT OF MINIMAL RESIDUAL DISEASE NEGATIVITY IN NEWLY DIAGNOSED MULTIPLE MYELOMA

Francesca BONELLO | Torino

RISK OF EARLY SEVERE INFECTIONS IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL AGENTS: A POOLED ANALYSIS

Matteo Claudio DA VIA' | Milano

BIALLELIC DELETION OF CHROMOSOME 16P ENCOMPASSING THE BCMA LOCUS AS A TUMOR-INTRINSIC RESISTANCE MECHANISM TO BCMA-DIRECTED CAR T IN MULTIPLE MYELOMA

Mattia D'AGOSTINO | Torino

GAIN AND AMPLIFICATION OF 1Q IMPAIR THE PROGNOSIS OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING CARFILZOMIB-BASED TREATMENT IN THE FORTE TRIAL

Chiara FAVINI | Novara

MUTATIONS OF THE EXPORTIN 1 (XPO1) GENE PREDICT SHORTER TIME TO FIRST TREATMENT IN 1092 EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A TRAINING/VALIDATION STUDY

Simone FERRERO | Torino

PHARMACOGENOMICS DRIVES LENALIDOMIDE EFFICACY AND MRD KINETICS IN MANTLE CELL LYMPHOMA AFTER AUTOLOGOUS TRANSPLANTATION: RESULTS FROM THE MCL0208 MULTICENTER, PHASE III, RANDOMIZED CLINICAL TRIAL FROM THE FONDAZIONE ITALIANA LINFOMI (FIL)

Valentina FERRI | Novara

DISSECTING DIFFERENT ANATOMICAL COMPARTMENTS OF SMALL LYMPHOCYTIC LYMPHOMA WITH A LIQUID BIOPSY APPROACH

Juri Alessandro GIANNOTTA | Milano

ANALISI DELLE MICROVESICOLE CIRCOLANTI E DELLE CITOCHINE IMMUNOREGOLATORIE NELLE ANEMIE EMOLITICHE CONGENITE E ACQUISITE

Daniele GRIMALDI | Torino

KINETICS OF MINIMAL RESIDUAL DISEASE (MRD) DURING LENALIDOMIDE MAINTENANCE IN MANTLE CELL LYMPHOMA: RESULTS FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 MULTICENTER, PHASE III, RANDOMIZED CLINICAL TRIAL

Cristina MUZI | Milano

IBRUTINIB COMPARED TO STANDARD THERAPY IN CNS RELAPSE OF MANTLE CELL LYMPHOMA

Francesca Maria QUAGLIA | Verona

OUTCOMES IN FIRST RELAPSED-REFRACTORY YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: RESULTS FROM THE MANTLE-FIRST STUDY

Francesca SCHIEPPATI | Bergamo

LOW LEVELS OF ADAMTS-13 WITH HIGH ANTI-ADAMTS-13 ANTIBODIES DURING REMISSION OF IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA HIGHLY PREDICT FOR DISEASE RELAPSE: A MULTI-INSTITUTIONAL STUDY.

Gian Maria ZACCARIA | Bari

DEVELOPMENT OF A CLINICAL PROGNOSTIC MODEL BASED ON MACHINE LEARNING: APPLICATION TO THE DATASET OF THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 PHASE III TRIAL

SESSIONE STUDI RICERCA DI BASE

Anna Maria APRILE | Milano

HEMATOPOIETIC STEM CELL FUNCTION IN β -THALASSEMIA IS IMPAIRED AND IS RESCUED BY TARGETING THE BONE MARROW NICHE

Carolina CASERTA | Milano

MIR-126 IS EPIGENETICALLY REGULATED AND IDENTIFIES A CHEMO-REFRACTORY BLAST SUBSET IN HUMAN BCELL ACUTE LYMPHOBLASTIC LEUKEMIA

Giacomo COLTRO | Firenze

RAS/CBL MUTATIONS PREDICT RESISTANCE TO JAK INHIBITORS AND ARE ASSOCIATED WITH POOR PROGNOSTIC FEATURES IN MYELOFIBROSIS

Silvia COLUCCI | Heidelberg (DE)

INCREASED HEPATOCYTE IRON CONTENT INDUCES BMP6 EXPRESSION IN LIVER SINUSOIDAL ENDOTHELIAL CELLS TO CONTROL SYSTEMIC IRON HOMEOSTASIS

Anair Graciela LEMA FERNANDEZ | Perugia

THE EPIGENETIC LANDSCAPE OF CYTOGENETIC HALLMARKS OF MYELOID NEOPLASMS

Marta LIONETTI | Milano

APPLICATION OF NEXT-GENERATION SEQUENCING FOR GENOMIC CHARACTERIZATION OF PATIENTS WITH SMOLDERING MYELOMA

Enrico MILAN | Milano

THE INTERACTION OF THE TUMOR SUPPRESSOR FAM46C WITH P62 AND FNDC3 PROTEINS INTEGRATES PROTEIN AND SECRETORY HOMEOSTASIS

Matteo Maria NALDINI | Milano

LONGITUDINAL TRACING OF AML STEM CELLS AT SINGLE CELL RESOLUTION UNCOVERS PATHWAYS TOWARDS RELAPSED AND REFRACTORY DISEASE

Violante OLIVARI | Milano

TARGETING TRANSFERRIN RECEPTOR 2 AMELIORATES ANEMIA IN A MURINE MODEL OF CHRONIC KIDNEY DISEASE

Alice Silvia PIEVANI | Monza

ACUTE MYELOID LEUKEMIA SHAPES THE BONE MARROW STROMAL NICHE IN VIVO

Simone RAGAINI | Torino

A THREE-GENES IMMUNE SIGNATURE INCLUDING IDO1, BIN1 AND PLXNC1 PREDICTS SURVIVAL IN ACUTE MYELOID LEUKEMIA

Giorgia SCAPIN | Boston (MA)

TRANSGENE-FREE GENERATION OF LONG-TERM HEMATOPOIETIC STEM CELLS

Filippo SEVERIN | Padova

INHIBITION OF A MITOCHONDRIAL POTASSIUM CHANNEL SELECTIVELY TRIGGERS CLL B LYMPHOCYTE APOPTOSIS IN VIVO

Silvia ZANINELLI | Bergamo

IN VITRO FUNCTIONAL ACTIVITY COMPARISON BETWEEN UNMODIFIED CIK CELLS PLUS BISPECIFIC ANTIBODY AND ANTI-CD19 CAR CIK CELLS

Bachisio ZICCHEDDU | Milano

REVEALING TRANSCRIPTOME DEREGLATION UPON GENOMIC COMPLEXITY IN MULTIPLE MYELOMA

POSTER

Chiara CALABRESE | Torino

DEFERASIROX-DEPENDENT IRON CHELATION IN MYELODYSPLASTIC PATIENTS

Silvia COLUCCI | Heidelberg (DE)

MUTATIONS IN TRANSFERRIN RECEPTOR 1 CAUSE A NOVEL SUBTYPE OF IRIDA

Matteo DRAGANI | Torino

TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA HARBORING ATYPICAL BCR-ABL1 TRANSCRIPTS.

Francesca FAZIO | Roma

THERAPY REGIMENS INCLUDING DARATUMUMAB FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) PATIENTS: REPORT FROM THE MULTIPLE MYELOMA GIMEMA LAZIO GROUP

Susanna GRASSI | Pisa

THE COV-2 OUTBREAK: HOW HEMATOLOGISTS COULD HELP TO FIGHT COVID-19

Carmelo GURNARI | Roma

IMPLICATION OF PIGA GENOTYPE ON CLINICAL FEATURES OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

Fabrizio PUGLISI | Catania

ADAPTIVE RESPONSE TO AMINOACID DEPRIVATION AS EMERGING BIOMARKER IN HL

Alessandra VENANZI | Perugia

TRACKING CLONAL HEMATOPOIESIS IN CLASSICAL HODGKIN LYMPHOMA